This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.
Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track
by Zacks Equity Research
Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $158.58, moving +0.7% from the previous trading session.
Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.
J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III
by Zacks Equity Research
J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Personal Income Increased in December
by Zacks Equity Research
Personal Income Increased in December
Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.
Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data
by Mark Vickery
With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.
Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets
by Mark Vickery
The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.
Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19
by Zacks Equity Research
Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
Regeneron (REGN) Reports Positive Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infection.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?
by Zacks Equity Research
Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna
Top Stock Reports for NIKE, Amgen & Morgan Stanley
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).
Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX
by Zacks Equity Research
Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data